

# Drug Policy

<b>Policy:</b>	<b>Diacomit (stiripentol)</b>	<b>Annual Review Date:</b> <b>10/19/2023</b>  <b>Last Revised Date:</b> <b>10/19/2023</b>
----------------	-------------------------------	---

## OVERVIEW

Diacomit, an antiepileptic drug (AED), is indicated for the treatment of seizures associated with Dravet syndrome in patients  $\geq 2$  years of age taking clobazam. There are no clinical data to support the use of Diacomit as monotherapy in Dravet syndrome. The mechanism by which Diacomit exerts its anticonvulsant effect is not known. Possible mechanisms of action include direct effects mediated through the gamma-aminobutyric acid (GABA)<sub>A</sub> receptor and indirect effects involving inhibition of cytochrome P450 (CYP) activity with resulting increase in blood levels of clobazam and its active metabolite.

## POLICY STATEMENT

This policy involves the use of Diacomit. Prior authorization is recommended for pharmacy benefit coverage of Diacomit. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

Because of the specialized skills required for evaluation and diagnosis of patients treated with Diacomit as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Diacomit be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below.

## RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Diacomit is recommended in those who meet the following criteria:

### 1. Dravet Syndrome

**Criteria.** *Patient must meet the following criteria*

- A. The patient is 6 months of age or older; AND
- B. The patient weighs at least 7 kg or more; AND
- C. Diacomit is prescribed by or in consultation with a neurologist; AND
- D. Diacomit will be used in combination with clobazam

### 2. Dravet Syndrome, continuation of therapy

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

# Drug Policy

**Criteria.** *Patient must meet the following criteria*

- A. The patient has had a beneficial response to medication (e.g. reduced seizure severity, frequency, and/or duration) as determined by the prescribing physician; AND
- B. Diacomit will continue to be used in combination with clobazam

## **Initial Approval/ Extended Approval.**

A) *Initial Approval:* 1 year

B) *Extended Approval:* 1 year

---

## **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Diacomit has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. **Use of Diacomit as Monotherapy in Dravet Syndrome.** There are no clinical data to support the use of Diacomit as monotherapy for the treatment of Dravet Syndrome.
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## **Documentation Requirements:**

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

## **REFERENCES**

1. Diacomit® capsules and oral suspension [prescribing information]. Redwood City, CA: Biocodex; July 2022.
2. Dravet Foundation – Dravet Syndrome. Available at: <https://www.dravetfoundation.org/what-is-dravet-syndrome/>. Accessed on December 31, 2018.
3. Shafer PO. Epilepsy Foundation – Dravet Syndrome. Updated June 2017. Available at: <https://www.epilepsy.com/learn/types-epilepsy-syndromes/dravet-syndrome>. Accessed on December 31, 2018.
4. Knupp KG, Wirrell EC. Treatment Strategies for Dravet Syndrome. *CNS Drugs*. Apr;32(4):335-350.
5. Wirrell EC, Laux L, Donner, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American Consensus Panel. *Pediatr Neurol*. 2017;68:18-34.

---

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

# Drug Policy

6. Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. *Epilepsia*. 1999;40(11):1618-1626.
7. Perry MS. Expanded access use of stiripentol in Dravet syndrome or sodium channel mutation epileptic encephalopathies. In: *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2018 Dec 31]. Available at: <https://www.clinicaltrials.gov/ct2/show/NCT02239276?term=stiripentol&rank=2>. NLM Identifier: NCT02239276.
8. Center for Drug Evaluation and Research. Clinical review of Diacomit. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2018/206709Orig1s000.207223Orig1s000MedR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000.207223Orig1s000MedR.pdf). Accessed on December 31, 2018.
9. Stiripentol. In: DRUGDEX [online database]. Truven Health Analytics; Greenwood Village, CO. Last updated 27 July 2020. Accessed on 18 November 2021.